Pharmacogenetics of Psychoactive Drugs

Pharmacogenomics in Clinical Therapeutics

Volumn , Issue , 2012, Pages 144-175

  Sepulveda, Jorge L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CYP2C19 genotyping; CYP2D6 genotyping; psychotropic drugs; SSRI; Tricyclic antidepressant

Indexed keywords

EID: 84862838011     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959601.ch9     Document Type: Chapter

References (246)

1. Sullivan, P.F., Kendler, K.S., Neale, M.C. (2003) Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry, 60(12), 1187-1192.
2. Sullivan, P.F., Neale, M.C., Kendler, K.S. (2000) Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry, 157(10), 1552-1562.
3. Craddock, N., Sklar, P. (2009) Genetics of bipolar disorder: successful start to a long journey. Trends Genet, 25(2), 99-105.
4. Maron, E., Hettema, J.M., Shlik, J. (2010) Advances in molecular genetics of panic disorder. Mol Psychiatry, 15(7), 681-701.
5. Burt, S.A. (2009) Rethinking environmental contributions to child and adolescent psychopathology: a meta-analysis of shared environmental influences. Psychol Bull, 135(4), 608-637.
6. Rhee, S.H., Waldman, I.D. (2002) Genetic and environmental influences on antisocial behavior: a metaanalysis of twin and adoption studies. Psychol Bull, 128(3), 490-529.
7. Hettema, J.M., Neale, M.C., Kendler, K.S. (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry, 158(10), 1568-1578.
8. Agrawal, A., Prescott, C.A., Kendler, K.S. (2004) Forms of cannabis and cocaine: a twin study. Am J Med Genet B Neuropsychiatr Genet, 129B(1), 125-128.
9. Penno, M.B., Dvorchik, B.H., Vesell, E.S. (1981) Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. Proc Natl Acad Sci U S A, 78(8), 5193-5196.
10. Wang, P.S., Simon, G., Kessler, R.C. (2003) The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res, 12(1), 22-33.
11. Gonzalez, H.M., et al. (2010) Depression care in the United States: too little for too few. Arch Gen Psychiatry, 67(1), 37-46.
12. EGAPP Working Group (2007) Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med, 9(12), 819-825.
13. Agius, M., et al. (2010) What do large scale studies of medication in schizophrenia add to our management strategies? Psychiatr Danub, 22(2), 323-328.
14. Nierenberg, A.A., et al. (2010) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med, 40(1), 41-50.
15. American Psychiatric Association (2010) Treatment of Patients with Major Depressive Disorder, 3rd ed. [WWW document] URL http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx [accessed on 28 June 2011].
16. McEvoy, J.P., et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 163(4), 600-610.
17. Phillips, K.A., et al. (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA, 286(18), 2270-2279.
18. Puls, I., Gallinat, J. (2008) The concept of endophenotypes in psychiatric diseases meeting the expectations? Pharmacopsychiatry, 41(Suppl. 1), S37-S43.
19. Kirchheiner, J., et al. (2005) Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics, 15(8), 579-587.
20. Rabl, U., et al. (2010) Imaging genetics: implications for research on variable antidepressant drug response. Expert Review of Clinical Pharmacology, 3(4), 471-489.
21. Kirsch, I., et al. (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med, 5(2), e45.
22. Keers, R., Aitchison, K.J. (2011) Pharmacogenetics of antidepressant response. Expert Rev Neurother, 11(1), 101-125.
23. Kieling, C., et al. (2010) A current update on ADHD pharmacogenomics. Pharmacogenomics, 11(3), 407-419.
24. Kato, M., Serretti, A. (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry, 15(5), 473-500.
25. Le Foll, B., et al. (2009) Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol, 20(1), 1-17.
26. de Leon, J. (2009) The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res, 59(2), 81-89.
27. Allen, N.C., et al. (2008) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet, 40(7), 827-834.
28. Anttila, S., et al. (2009) TPH2 polymorphisms may modify clinical picture in treatment-resistant depression. Neurosci Lett, 464(1), 43-46.
29. Tsai, S.J., et al. (2009) Tryptophan hydroxylase 2 gene is associated with major depressionand antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry, 33(4), 637-641.
30. Lopez de Lara, C., et al. (2007) Effect of tryptophan hydroxylase-2 gene variants on suicide risk in major depression. Biol Psychiatry, 62(1), 72-80.
31. Roche, S., McKeon, P. (2009) Support for tryptophan hydroxylase-2 as a susceptibility gene for bipolar affective disorder. Psychiatr Genet, 19(3), 142-146.
32. Campos, S.B., et al. (2010) Association of polymorphisms of the tryptophan hydroxylase 2 gene with risk for bipolar disorder or suicidal behavior. J Psychiatr Res, 44(5), 271-274.
33. Wang, L., et al. (2007) Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett, 414(1), 1-4.
34. Kishi, T., et al. (2010) HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med, 12(3), 237-242.
35. Benmessaoud, D., et al. (2008) Excess of transmission of theGallele of the-1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry, 8, 40.
36. Correia, C.T., et al. (2010) Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J, 10(5), 418-430.
37. Souza, R.P., et al. (2010) Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics, 20(4), 274-276.
38. Gu, B., et al. (2008) Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics, 18(8), 721-727.
39. Schuhmacher, A., et al. (2009) Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics, 19(11), 843-851.
40. McAuley, E.Z., et al. (2009) Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. Psychiatr Genet, 19(5), 244-252.
41. Mazza, M., et al. (2010) Further evidence supporting the association between 5HTR2C gene and bipolar disorder. Psychiatry Res, 180(2-3), 151-152.
42. Meineke, C., et al. (2008) Functional characterization of a-100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene. Pharmacogenet Genomics, 18(3), 219-230.
43. Yosifova, A., et al. (2009) Case-control association study of 65 candidate genes revealed a possible association of a SNP of HTR5A to be a factor susceptible to bipolar disease in Bulgarian population. J Affect Disord, 117(1-2), 87-97.
44. Fanous, A.H., et al. (2009) Genetic variation in the serotonin 2A receptor and suicidal ideation in a sample of 270 Irish high-density schizophrenia families. Am J Med Genet B Neuropsychiatr Genet, 150B(3), 411-417.
45. Giegling, I., et al. (2006) Anger-and aggression-related traits are associated with polymorphisms in the 5-HT-2A gene. J Affect Disord, 96(1-2), 75-81.
46. Bevilacqua, L., et al. (2010) A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature, 468(7327), 1061-1066.
47. Giegling, I., et al. (2009) Tyrosine hydroxylase and DOPA decarboxylase gene variants in personality traits. Neuropsychobiology, 59(1), 23-27.
48. Ribases, M., et al. (2009) Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol Psychiatry, 14(1), 71-85.
49. Shumay, E., Fowler, J.S., Volkow, N.D. (2010) Genomic features of the human dopamine transporter gene and its potential epigenetic states: implications for phenotypic diversity. PLoS One, 5(6), e11067.
50. Rohde, L.A., et al. (2003) Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study. Synapse, 48(2), 87-89.
51. Ma, J.Z., et al. (2005) Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependence. Hum Mol Genet, 14(12), 1691-1698.
52. Lane, H.Y., et al. (2004) Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol, 7(4), 461-470.
53. Adams, D.H., et al. (2008) Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol, 23(4), 267-274.
54. Tsutsumi, A., et al. (2009) Genetic polymorphisms in dopamine-and serotonin-related genes and treatment responses to risperidone and perospirone. Psychiatry Investig, 6(3), 222-225.
55. Gasso, P., et al. (2009) Acommon variant inDRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J, 9(6), 404-410.
56. Tsai, H.T., et al. (2010) The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a metaanalysis. Am J Med Genet B Neuropsychiatr Genet, 153B(1), 57-66.
57. Zai, C.C., et al. (2009) Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J, 9(3), 168-174.
58. Zai, C.C., et al. (2007) Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol, 10(5), 639-651.
59. Muller, D.J., et al. (2010) Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychoticinduced weight gain. Pharmacogenomics J, epub 17 August.
60. Lasky-Su, J., et al. (2008) Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet, 147B(8), 1345-1354.
61. Doehring, A., Kirchhof, A., Lotsch, J. (2009) Genetic diagnostics of functional variants of the human dopamine D2 receptor gene. Psychiatr Genet, 19(5), 259-268.
62. Hess, C., et al. (2009) A functional dopamine-betahydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. J Neural Transm, 16(2), 121-130.
63. Yamamoto, K., et al. (2003) Dopamine beta-hydroxylase (DBH) gene and schizophrenia phenotypic variability: a genetic association study. Am J Med Genet B Neuropsychiatr Genet, 117B(1), 33-38.
64. Kopeckova, M., Paclt, I., Goetz, P. (2006) Polymorphisms and low plasma activity of dopamine-betahydroxylase in ADHD children. Neuro Endocrinol Lett, 27(6), 748-754.
65. Faraone, S.V., Khan, S.A. (2006) Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry, 67(Suppl. 8), 13-20.
66. Bosker, F.J., et al. (2010) Poor replication of candidate genes for major depressive disorder using genomewide association data. Mol Psychiatry, epub 30 March.
67. Dong, C., Wong, M.L., Licinio, J. (2009) Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry, 14(12), 1105-1118.
68. Dlugos, A.M., et al. (2009) Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology (Berl), 206(3), 501-511.
69. Ramoz, N., et al. (2009) A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attentiondeficit hyperactivity disorder (ADHD). Neuropsychopharmacology, 34(9), 2135-2142.
70. Kim, J.W., et al. (2008) Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. Mol Psychiatry, 13(6), 624-630.
71. Polanczyk, G., et al. (2007) Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 64(2), 218-224.
72. Comings, D.E., et al. (1999) Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin Genet, 55(3), 160-172.
73. Liu, Y.R., et al. (2010) ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J, 10(1), 30-39.
74. Sickert, L., et al. (2009) Association of the alpha 2A adrenergic receptor-1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics, 10(7), 1169-1176.
75. Ujike, H., et al. (2008) Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry, 69(9), 1416-1422.
76. Zalsman, G., et al. (2011) Association of polymorphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: a multi-center study. World J Biol Psychiatry, 12(1), 33-41.
77. Grigorenko, E.L., et al. (2010) Aggressive behavior, related conduct problems, and variation in genes affecting dopamine turnover. Aggress Behav, 36(3), 158-176.
78. Kinnally, E.L., et al. (2009) Parental care moderates the influence of MAOA-uVNTR genotype and childhood stressors on trait impulsivity and aggression in adult women. Psychiatr Genet, 19(3), 126-133.
79. Barnett, J.H., et al. (2009) Effects of catechol-O-methyltransferase on normal variation in the cognitive function of children. Am J Psychiatry, 166(8), 909-916.
80. Liao, S.Y., et al. (2009) Genetic variants in COMT and neurocognitive impairment in families of patients with schizophrenia. Genes Brain Behav, 8(2), 228-237.
81. Illi, A., et al. (2010) Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Res, 176(1), 85-87.
82. Perlis, R.H., et al. (2009) Variation in catechol-Omethyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry, 65(9), 785-791.
83. Benedetti, F., et al. (2009) The catechol-O-methyltransferase Val (108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl), 203(1), 155-160.
84. Swart, M., et al. (2011) COMT Val158Met polymorphism, verbalizing of emotion and activation of affective brain systems. Neuroimage, 55(1), 338-344.
85. Finan, P.H., et al. (2011) COMT moderates the relation of daily maladaptive coping and pain in fibromyalgia. Pain, 152(2), 300-307.
86. Rakvag, T.T., et al. (2005) The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Piain, 116(1-2), 73-78.
87. Voisey, J., et al. (2010) HapMap tag-SNP analysis confirms a role forCOMTin schizophrenia risk and reveals a novel association. Eur Psychiatry, epub 7 October.
88. Costas, J., et al. (2011) Heterozygosity at catechol-OmethyltransferaseVal158Met and schizophrenia:new data and meta-analysis. J Psychiatr Res, 45(1), 7-14.
89. Chien, Y.L., et al. (2009) Association of the 30 region of COMT with schizophrenia in Taiwan. J Formos Med Assoc, 108(4), 301-309.
90. Hoenicka, J., et al. (2010) Gender-specific COMT Val158Met polymorphism association in Spanish schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet, 153B(1), 79-85.
91. Gupta, M., et al. (2009) Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics, 10(3), 385-397.
92. Need, A.C., et al. (2009) Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet, 17(7), 946-957.
93. Lohoff, F.W. (2010) Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders. Methods Mol Biol, 637, 165-180.
94. De Ruyck, K., et al. (2010) Genetic variation in three candidate genes and nicotine dependence, withdrawal and smokingcessationinhospitalized patients. Pharmacogenomics, 11(8), 1053-1063.
95. Thorgeirsson, T.E., et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature, 452(7187), 638-642.
96. Schlaepfer, I.R., et al. (2008) The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry, 63(11), 1039-1046.
97. Ancin, I., et al. (2010) Evidence for association of the non-duplicated region of CHRNA7 gene with bipolar disorder but not with schizophrenia. Psychiatr Genet 20 (6), 289-297.
98. Carson, R., et al. (2008) Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. Neuromolecular Med, 10(4), 377-384.
99. Cannon, D.M., et al. (2010) Genetic variation in cholinergic muscarinic-2 receptor gene modulates M (2) receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry, epub 30 March.
100. Scarr, E., et al. (2009) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry, 14(11), 1017-1023.
101. Ray, R., et al. (2010) Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology, 35(6), 1374-1382.
102. Grunblatt, E., et al. (2009) Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J Psychiatr Res, 43(3), 298-308.
103. Deng, X., et al. (2004) Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry, 4, 21.
104. Gadow, K.D., et al. (2010) Glutamate transporter gene (SLC1A1) single nucleotide polymorphism(rs301430) and repetitive behaviors and anxiety in children with autism spectrum disorder. J Autism Dev Disord, 40(9), 1139-1145.
105. Wendland, J.R., et al. (2009) A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry, 66(4), 408-416.
106. Kwon, J.S., et al. (2009) Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry, 66(11), 1233-1241.
107. Chiu, H.J., et al. (2003) Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese. Neuropsychobiology, 47(4), 178-181.
108. Horstmann, S., et al. (2010) Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology, 35(3), 727-740.
109. Paddock, S., et al. (2007) Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry, 164(8), 1181-1188.
110. Tsunoka, T., et al. (2009) Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog Neuropsychopharmacol Biol Psychiatry, 33(5), 875-879.
111. Laje, G., et al. (2009) Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv, 60(11), 1446-1457.
112. Laje, G., et al. (2007) Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry, 164(10), 1530-1538.
113. Perlis, R.H., et al. (2009) A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry, 166(6), 718-725.
114. Du, J., et al. (2008) Comprehensive analysis of polymorphisms throughout GAD1 gene: a family-based association study in schizophrenia. J Neural Transm, 115(3), 513-519.
115. Barnby, G., et al. (2005) Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT. Am J Hum Genet, 76(6), 950-966.
116. Inada, T., et al. (2008) Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics, 18(4), 317-323.
117. Chavarria-Siles, I., et al. (2008) Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 147(3), 279-284.
118. Juhasz, G., et al. (2009) CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology, 34(8), 2019-2027.
119. Domschke, K., et al. (2008) Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol, 18(10), 751-759.
120. Tiwari, A.K., et al. (2011) Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J, epub 25 January.
121. Tiwari, A.K., et al. (2010) A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology, 35(6), 1315-1324.
122. Schacht, J.P., Selling, R.E., Hutchison, K.E. (2009) Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis. Psychopharmacology (Berl), 203(3), 511-517.
123. Flanagan, J.M., et al. (2006) The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet, 120(4), 581-588.
124. Giegling, I., et al. (2010) Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenet Genomics, epub 18 September.
125. Lotrich, F.E., Pollock, B.G. (2005) Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatr Dis Treat, 1(1), 17-35.
126. Liu, Z., et al. (2007) Association study of corticotropinreleasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett, 414(2), 155-158.
127. Ferreira, M.A., et al. (2008) Collaborative genomewide association analysis supports a role forANK3and CACNA1C in bipolar disorder. Nat Genet, 40(9), 1056- 1058.
128. Silberberg, G., et al. (2008) Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet Genomics, 18(5), 403-412.
129. Lazary, J., et al. (2011) Epistatic interaction of CREB1 and KCNJ6 on rumination and negative emotionality. Eur Neuropsychopharmacol, 21(1), 63-70.
130. Liou, Y.J., et al. (2009) Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment. Pharmacogenet Genomics, 19(10), 735-741.
131. Borsotto, M., et al. (2007) PP2A-Bgamma subunit and KCNQ2 K{thorn} channels in bipolar disorder. Pharmacogenomics J, 7(2), 123-132.
132. Tsai, S.J., et al. (2008) Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J, 8(6), 384-390.
133. Ikeda, M., et al. (2008) Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics, 9(10), 1437-1443.
134. Luo, H.R., et al. (2009) Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatr Dis Treat, 5, 163-170.
135. Wong, M.L., et al. (2006) Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad SciU S A, 103(41), 15124-15129.
136. Kirchheiner, J., et al. (2008) Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics, 9(7), 841-846.
137. McHugh, P.C., et al. (2010) A polymorphism of the GTP-cyclohydrolase I feedback regulator gene alters transcriptional activity and may affect response to SSRI antidepressants. Pharmacogenomics J, epub 30 March.
138. Kohlrausch, F.B., et al. (2008) G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics 9 (10), 1429-1436.
139. Zill, P., et al. (2000) Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport, 11(9), 1893-1897.
140. Peerbooms, O.L., et al. (2010) Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun, epub 24 December.
141. Gilbody, S., Lewis, S., Lightfoot, T. (2007) Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol, 165(1), 1-13.
142. Stefansson, H., et al. (2009) Common variants conferring risk of schizophrenia. Nature, 460(7256), 744-747.
143. Mori, A., et al. (2005) UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos, 33(5), 672-675.
144. Zhou, S.F. (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet, 48(11), 689-723.
145. Kirchheiner, J., et al. (2011) CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry, 16(3), 333-341.
146. Dorado, P., Penas-Lledo, E.M., Llerena, A. (2007) CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics, 8(11), 1597-1608.
147. Bromek, E., Haduch, A., Daniel, W.A. (2010) The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: an in vitro study. Eur J Pharmacol, 626(2-3), 171-178.
148. Yu, A.M., et al. (2003) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics, 13(3), 173-181.
149. Sridar, C., Snider, N.T., Hollenberg, P.F. (2011) Anandamide oxidation by wild type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos, epub 24 February.
150. Sim, S.C., et al. (2010) Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet, 153B(6), 1160-1166.
151. Rudberg, I., et al. (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther, 83(2), 322-327.
152. Ohlsson Rosenborg, S., et al. (2008) Kinetics of omeprazole and escitalopramin relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol, 64(12), 1175-1179.
153. Rudberg, I., et al. (2008) Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol, 64(12), 1181-1188.
154. Li-Wan-Po, A., et al. (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol, 69(3), 222-230.
155. Laika, B., et al. (2010) Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J, 10(1), 20-29.
156. Uhr, M., et al. (2008) Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron, 57(2), 203-209.
157. Rosenhagen, M.C., Uhr, M. (2010) Single nucleotide polymorphism in the drug transporter gene ABCB1 in treatment-resistant depression: clinical practice. J Clin Psychopharmacol, 30(2), 209-211.
158. Roberts, R.L., et al. (2002) A common P-glycoprotein polymorphism is associated with nortriptylineinduced postural hypotension in patients treated for major depression. Pharmacogenomics J, 2(3), 191-196.
159. Hodges, L.M., et al. (2011) Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein. Pharmacogenet Genomics, 2011. 21(3), 152-61.
160. Watanabe, T., et al. (2010) Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). Pharmacogenet Genomics, 20(7), 459-462.
161. Yu, K.S., et al. (2001) Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther, 69(4), 266-273.
162. Cho, J.Y., et al. (2002) Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygoticEMgenotype for CYP2C19. Br J Clin Pharmacol, 53(4), 393-397.
163. Kamada, T., et al. (2002) Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet, 17(3), 199-206.
164. de Leon, J. (2007) The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol, 27(3), 241-245.
165. Bijl, M.J., et al. (2008) Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol, 65(4), 558-564.
166. Hendset, M., et al. (2006) The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry, 39(4), 121-127.
167. de Vos, A., van der Weide, J., Loovers, H.M. (2010) Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J, epub 6 June.
168. Schenk, P.W., et al. (2010) The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J, 10(3), 219-225.
169. Kirchheiner, J., et al. (2003) Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol, 23(5), 459-466.
170. Koski, A., et al. (2007) A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol, 28(3), 259-261.
171. Venkatakrishnan, K., et al. (1998) Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol, 38(2), 112-121.
172. Koyama, E., et al. (1997) Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther, 281(3), 1199- 1210.
173. de Leon, J., Arranz, M.J., Ruano, G. (2008) Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med, 28(4), 599-617.
174. Brachtendorf, L., et al. (2002) Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol, 90(3), 144-149.
175. Wolf, C.R., Smith, G., Smith, R.L. (2000) Science, medicine, and the future: Pharmacogenetics. BMJ, 320(7240), 987-990.
176. Anttila, A.K., Rasanen, L., Leinonen, E.V. (2001) Fluvoxamine augmentation increases serum mirtazapine concentrations three-to fourfold. Ann Pharmacother, 35(10), 1221-3.
177. Lind, A.B., et al. (2009) Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet, 48(1), 63-70.
178. Kirchheiner, J., et al. (2004) Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol, 24(6), 647-652.
179. Kirchheiner, J., et al. (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry, 9(5), 442-73.
180. Grasmader, K., et al. (2004) Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol, 60(5), 329-336.
181. Charlier, C., et al. (2003) Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit, 25(6), 738-742.
182. Scordo, M.G., et al. (2005) Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol, 97(5), 296-301.
183. Llerena, A., et al. (2004) Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol, 59(12), 869-873.
184. Liu, Z.Q., et al. (2001) Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin, 22(1), 85-90.
185. Laika, B., et al. (2009) Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening[quest]. Pharmacogenomics J, 9(6), 395-403.
186. Sato, A., et al. (2004) Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5. Mayo Clin Proc, 79(11), 1444-1448.
187. Lin, K.M., et al. (2010) CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics, 11(11), 1535-1543.
188. Suzuki, Y., et al. (2010) CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol, epub 14 June.
189. Katoh, Y., et al. (2010) Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol Pharm Bull, 33(2), 285-288.
190. Tsai, M.H., et al. (2010) Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics, 11(4), 537-546.
191. Jin, Y., et al. (2010) Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol, 50(1), 62-72.
192. Noehr-Jensen, L., et al. (2009) Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol, 65(9), 887-894.
193. Levin, T.T., et al. (2008) Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion. Gen Hosp Psychiatry, 30(4), 372-377.
194. Mrazek, D.A., et al. (2011) CYP2C19 variation and citalopram response. Pharmacogenet Genomics, 21(1), 1-9.
195. Yin, O.Q., et al. (2006) Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol, 26(4), 367-372.
196. Fudio, S., et al. (2010) Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol, 626(2-3), 200-204.
197. Peters, E.J., et al. (2008) Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One, 3(4), e1872.
198. Obach, R.S., Cox, L.M., Tremaine, L.M. (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamineoxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos, 33(2), 262-270.
199. Xu, Z.H., et al. (1999) Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol, 48(3), 416-423.
200. McAlpine, D.E., et al. (2007) Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc, 82(9), 1065-1068.
201. Shams, M.E., et al. (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther, 31(5), 493-502.
202. Lessard, E., et al. (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics, 9(4), 435-443.
203. Lobello, K.W., et al. (2010) Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry, 71(11), 1482-1487.
204. Preskorn, S.H. (2010) Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. J Psychiatr Pract, 16(1), 46-49.
205. Launiainen, T., et al. (2010) Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med, epub 30 April.
206. McAlpine, D.E., et al. (2011) Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit, 33(1), 14-20.
207. Fukuda, T., et al. (2000) The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol, 56(2), 175-180.
208. Knadler, M.P., et al. (2011) Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet, epub 2 March.
209. Foley, K.F., DeSanty, K.P., Kast, R.E. (2006) Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother, 6(9), 1249-1265.
210. Kirchheiner, J., et al. (2003) Bupropion and 4-OHbupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics, 13(10), 619-626.
211. Rotzinger, S., et al. (1998) HumanCYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry, 44(11), 1185-1191.
212. Wen, B., et al. (2008) Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos, 36(5), 841-850.
213. Aklillu, E., et al. (2007) CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics, 17(11), 989-993.
214. Llerena, A., et al. (2004) Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry, 37(2), 69-73.
215. Desai, M., et al. (2003) Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J, 3(2), 105-113.
216. Brockmoller, J., et al. (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther, 72(4), 438-452.
217. Park, J.Y., et al. (2006) Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol, 26(2), 135-142.
218. Ohara, K., et al. (2003) Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry, 27(6), 945-949.
219. Athanasiou, M.C., et al. (2010) Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry.
220. Jaquenoud Sirot, E., et al. (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol, 29(4), 319-326.
221. vanderWeide, J., Steijns, L.S., vanWeelden, M.J. (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphismonclozapine clearance and dose requirement. Pharmacogenetics, 13(3), 169-172.
222. Eap, C.B., et al. (2004) Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol, 24(2), 214-219.
223. Brouwers, E.E., et al. (2009) Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig, 29(1), 59-63.
224. Arranz, M.J., et al. (1995) Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol, 39(4), 417-420.
225. de Leon, J., Wynn, G., Sandson, N.B. (2010) The pharmacokinetics of paliperidone versus risperidone. Psychosomatics, 51(1), 80-88.
226. Urichuk, L., et al. (2008) Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab, 9(5), 410-418.
227. Yasui-Furukori, N., et al. (2003) Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol, 43(2), 122-1227.
228. Scordo, M.G., et al. (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl), 147(3), 300-305.
229. Troost, P.W., et al. (2007) Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol, 27(1), 52-57.
230. Riedel, M., et al. (2005) Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci, 255(4), 261-268.
231. Huang, M.L., et al. (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther, 54(3), 257-268.
232. de Leon, J., et al. (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry, 66(1), 15-27.
233. de Leon, J., Armstrong, S.C., Cozza, K.L. (2006) Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics, 47(1), 75-85.
234. Llerena, A., et al. (2004) QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol, 18(2), 189-193.
235. Yasui-Furukori, N., et al. (2004) Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol, 57(5), 569-575.
236. Xing, Q., et al. (2006) Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics, 7(7), 987-993.
237. Nakagami, T., et al. (2005) Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther, 78(1), 43-51.
238. Kirchheiner, J.S.A., Viviani, R., Hodgkinson, S. (2010) One tablet or two? Towards the development of pharmacogenomically informed drug dose individualization. In: K.W. Schwab & E. Spina (eds), Pharmacogenomics in Psychiatry, 1-11. Krager, Basel.
239. Rodriguez-Antona, C., et al. (2009) CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics, 10(4), 685-699.
240. Suzuki, T., et al. (2011) Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit, 33(1), 21-24.
241. Swainston Harrison, T., Perry, C.M. (2004) Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs, 64(15), 1715-1736.
242. Lin, Y.C., et al. (2006) The relationship between Pglycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit, 28(5), 668-672.
243. Prior, T.I., Baker, G.B. (2003) Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci, 28(2), 99-112.
244. Nikisch, G., et al. (2010) Cytochrome P450 and ABCB1 genetics:associationwithquetiapineandnorquetiapine plasmaandcerebrospinalfluidconcentrationsandwith clinical response in patients suffering fromschizophrenia: a pilot study. J Psychopharmacol, epub 8 December.
245. Sistonen, J., et al. (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics, 17(2), 93-101.
246. Seeringer, A., Kirchheiner, J. (2008) Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med, 28(4), 619-626.